Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Key takeaways of recent quarter & conference call highlights
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Fujifilm India recently introduced a “Covid-19 Pneumonia Image Analysis Program” that helps in diagnosing chest CT images that helps in findings of Covid-19 pneumonia
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
